Tomas Leanderson (Former)
41 – 50 of 84
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
From the fetal liver to spleen and gut: the highway to natural antibody
(
- Contribution to journal › Article
-
Mark
Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.
(
- Contribution to journal › Article
- 2008
-
Mark
A subset of dendritic cells express joining chain (J-chain) protein
(
- Contribution to journal › Article
-
Mark
Effect on interferon-inducible gene expression signature by ABR215757, a new drug in development for SLE
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.567-568(
- Contribution to journal › Published meeting abstract
-
Mark
IFN-alpha/beta signaling is required for polarization of cytokine responses toward a protective type 1 pattern during experimental cryptococcosis
(
- Contribution to journal › Article
- 2007
-
Mark
Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria
(
- Contribution to journal › Article
- 2006
-
Mark
CArG box-binding factor-A interacts with multiple motifs in immunoglobulin promoters and has a regulated subcellular distribution.
(
- Contribution to journal › Article
-
Mark
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
(
- Contribution to journal › Article
-
Mark
Joining-chain (J-chain) negative mice are B cell memory deficient.
(
- Contribution to journal › Article
-
Mark
The kappa promoter penta-decamer binding protein CBF-A interacts specifically with nucleophosmin in the nucleus only.
(
- Contribution to journal › Article